TrialDiabetes, obesity & metabolism2023

Improvement of glycaemic control and treatment satisfaction by switching from liraglutide or dulaglutide to subcutaneous semaglutide in patients with type 2 diabetes: A multicentre, prospective, randomized, open-label, parallel-group comparison study (SWITCH-SEMA 1 study).

Yuka Takahashi et al.PubMed ↗Publisher ↗

No numbers read from the abstract.